[1]

Dua HS, Said DG, Messmer EM, Rolando M, Benitez-del-Castillo JM, et al. 2018. Neurotrophic keratopathy. Progress in Retinal and Eye Research 66:107−131

doi: 10.1016/j.preteyeres.2018.04.003
[2]

Sacchetti M, Komaiha C, Bruscolini A, Albanese GM, Marenco M, et al. 2022. Long-term clinical outcome and satisfaction survey in patients with neurotrophic keratopathy after treatment with cenegermin eye drops or amniotic membrane transplantation. Graefe's Archive for Clinical and Experimental Ophthalmology 260(3):917−925

doi: 10.1007/s00417-021-05431-6
[3]

Roszkowska AM, Inferrera L, Aragona E, Gargano R, Postorino EI, et al. 2022. Clinical and instrumental assessment of the corneal healing in moderate and severe neurotrophic keratopathy treated with rh-NGF (cenegermin). European Journal of Ophthalmology 32(6):3402−3410

doi: 10.1177/11206721221097584
[4]

Meduri A, Oliverio GW, Valastro A, Azzaro C, Camellin U, et al. 2022. Neurotrophic keratopathy in systemic diseases: a case series on patients treated with rh-NGF. Frontiers in Medicine 9:920688

doi: 10.3389/fmed.2022.920688
[5]

Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, et al. 2020. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. Ophthalmology 127(1):14−26

doi: 10.1016/j.ophtha.2019.08.020
[6]

Qu Y, Peng R, Hu B, Ma S, Liu Z, et al. 2024. A new treatment for recalcitrant neurotrophic keratopathy of ocular graft-versus-host disease with virus infection. Ophthalmology and Therapy 13(2):469−479

doi: 10.1007/s40123-023-00857-z
[7]

Hamrah P, Massaro-Giordano M, Schanzlin D, Holland E, Berdy G, et al. 2024. Phase IV multicenter, prospective, open-label clinical trial of cenegermin (rhNGF) for stage 1 neurotrophic keratopathy (DEFENDO). Ophthalmology and Therapy 13(2):553−570

doi: 10.1007/s40123-023-00866-y
[8]

Zidan AA, Gilbert JB, Goldberg E, Ross C, Elze T, et al. 2025. Nerve growth factor treatment for neurotrophic keratopathy in the IRIS® Registry. Ophthalmology 132(3):368−370

doi: 10.1016/j.ophtha.2024.10.036
[9]

Bonini S, Rama P, Olzi D, Lambiase A. 2003. Neurotrophic keratitis. Eye 17(8):989−995

doi: 10.1038/sj.eye.6700616
[10]

Bron AJ, Evans VE, Smith JA. 2003. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22(7):640−650

doi: 10.1097/00003226-200310000-00008
[11]

Hamrah P, Cruzat A, Dastjerdi MH, Zheng L, Shahatit BM, et al. 2010. Corneal sensation and subbasal nerve alterations in patients with herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology 117(10):1930−1936

doi: 10.1016/j.ophtha.2010.07.010
[12]

Blanco-Mezquita T, Martinez-Garcia C, Proença R, Zieske JD, Bonini S, et al. 2013. Nerve growth factor promotes corneal epithelial migration by enhancing expression of matrix metalloprotease-9. Investigative Ophthalmology & Visual Science 54(6):3880−3890

doi: 10.1167/iovs.12-10816
[13]

Labbé A, Alalwani H, Van Went C, Brasnu E, Georgescu D, et al. 2012. The relationship between subbasal nerve morphology and corneal sensation in ocular surface disease. Investigative Ophthalmology & Visual Science 53(8):4926−4931

doi: 10.1167/iovs.11-8708
[14]

Balbuena-Pareja A, Bogen CS, Cox SM, Hamrah P. 2023. Effect of recombinant human nerve growth factor treatment on corneal nerve regeneration in patients with neurotrophic keratopathy. Frontiers in Neuroscience 17:1210179

doi: 10.3389/fnins.2023.1210179
[15]

Li S, Xu J, Yuan J, Pan Z, Siri G, et al. 2025. Cenegermin for the treatment of moderate or severe neurotrophic keratopathy: results from a prospective, phase IV, open-label study in China. Ophthalmology and Therapy 14(12):3021−3033

doi: 10.1007/s40123-025-01253-5
[16]

Pedrotti E, Bonacci E, Chierego C, De Gregorio A, Cozzini T, et al. 2022. Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy. Orphanet Journal of Rare Diseases 17(1):63

doi: 10.1186/s13023-022-02237-5
[17]

Yavuz Saricay L, Bayraktutar BN, Lilley J, Mah FS, Massaro-Giordano M, et al. 2022. Efficacy of recombinant human nerve growth factor in stage 1 neurotrophic keratopathy. Ophthalmology 129(12):1448−1450

doi: 10.1016/j.ophtha.2022.08.014
[18]

Tervo T, Vannas A, Tervo K, Holden BA. 1985. Histochemical evidence of limited reinnervation of human corneal grafts. Acta Ophthalmologica 63(2):207−214

doi: 10.1111/j.1755-3768.1985.tb01535.x
[19]

Hyndiuk RA, Kazarian EL, Schultz RO, Seideman S. 1977. Neurotrophic corneal ulcers in diabetes mellitus. Archives of Ophthalmology 95(12):2193−2196

doi: 10.1001/archopht.1977.04450120099012
[20]

Mansoor H, Tan HC, Lin MT, Mehta JS, Liu YC. 2020. Diabetic corneal neuropathy. Journal of Clinical Medicine 9(12):3956

doi: 10.3390/jcm9123956
[21]

Roszkowska AM, Wylęgała A, Gargano R, Spinella R, Inferrera L, et al. 2021. Impact of corneal parameters, refractive error and age on density and morphology of the subbasal nerve plexus fibers in healthy adults. Scientific Reports 11(1):6076

doi: 10.1038/s41598-021-85597-5
[22]

Li Y, Yang H, Gao Y, He W. 2024. Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database. Expert Opinion on Drug Safety 23(3):385−391

doi: 10.1080/14740338.2023.2251389
[23]

Kanu LN, Ciolino JB. 2021. Nerve growth factor as an ocular therapy: applications, challenges, and future directions. Seminars in Ophthalmology 36(4):224−231

doi: 10.1080/08820538.2021.1890793